Disease burden

EyeCare Partners Announces New Refractive Cataract Anterior Segment Fellowship and Launch of ECP Foundation

Retrieved on: 
Thursday, April 4, 2024
Optical, Surgery, Health, Other Education, Philanthropy, Education, Foundation, Training, Disease burden, Partner, ECP, RCAS, Density, Intraocular lens, Growth, Convention, Refractive surgery, Physician, ASCRS, Telecanthus, Knowledge, Research, Meibomian gland dysfunction, Fellow, Trifocal lenses, Science, Patient satisfaction, Cataract, Mentorship, Quality of life, Surgeon, Society, Ophthalmology, Nursing

EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.

Key Points: 
  • EyeCare Partners (ECP), the nation’s leading provider of clinically integrated eye care, continues to advance leadership and research at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.
  • The company is launching two new initiatives to elevate eye care – the Refractive Cataract Anterior Segment (RCAS) Fellowship and the ECP Foundation.
  • This one-year program provides residency graduates comprehensive training in the latest advancements in refractive cataract and anterior segment surgeries.
  • “We implement this mission through three programs: ECP GIVES, ECP EDUCATES and ECP CARES,” said Amy Jones, ECP Foundation President.

The Inner Circle Acknowledges, Sandra Ann Ham as a Top Pinnacle Professional for her contributions as a Biostatistics Consultant

Retrieved on: 
Tuesday, June 27, 2023
Obesity, Theology, University, Kettering University, Education, SJ, Health, Disease, Public, Policy, Mechanical engineering, Social science, Research, Information management, Disease burden, Multimedia, Inner circle, CDC, University of Chicago Divinity School, Association of Christian Universities and Colleges in Asia, TRW, Korea Disease Control and Prevention Agency, Divinity, Master of Divinity, Biostatistics, Epidemiology, Social Problems, Global Burden of Disease Study, World Health Organization, Management, Science

BUFFALO, N.Y., June 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Sandra Ann Ham is acknowledged as a Top Pinnacle Professional for her contributions as a Biostatistics Consultant.

Key Points: 
  • BUFFALO, N.Y., June 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Sandra Ann Ham is acknowledged as a Top Pinnacle Professional for her contributions as a Biostatistics Consultant.
  • Ms. Ham pursued higher education at Kettering University where she earned a Bachelor of Science in Mechanical Engineering.
  • She noted that this prompted an in-depth study of epidemiological research and modeling methods that would shape the rest of her career.
  • Ms. Ham is currently a biostatistics consultant and owner of Sandra Ham Consulting serving clients.

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

Retrieved on: 
Thursday, March 9, 2023
Cream, Foam, Patient, Disease burden, Diagnosis, Health care, Itch, FAAD, Path, PASI, Poster, American Academy of Dermatology, Safety, AAD, Doctor of Philosophy, MD, Dermatitis, Ageing, Dermatology, Atopic dermatitis, American Academy, Pharmaceutical industry, Health insurance

Among these will be the presentation of late-breaking clinical data on roflumilast cream 0.15% in patients aged 6 years and older with atopic dermatitis from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 Phase 3 trials.

Key Points: 
  • Among these will be the presentation of late-breaking clinical data on roflumilast cream 0.15% in patients aged 6 years and older with atopic dermatitis from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 Phase 3 trials.
  • “The breadth of our scientific data being presented at AAD underscores Arcutis’ commitment to bring meaningful innovation to immuno-dermatology.
  • We are excited by the acceptance of our late-breaking data from the INTEGUMENT pivotal Phase 3 trials, which build strong evidence for the potential of roflumilast cream as an effective once-daily, steroid-free treatment for atopic dermatitis,” said Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer, Arcutis.
  • Efficacy and Safety of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Pooled PASI and PASI-HD Results From the DERMIS-1 and DERMIS-2 Phase 3 Trials
    Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Seborrheic Dermatitis in a Phase 3 Trial: Assessment of Pruritus
    The following poster will be available during the 19th Annual SOCS Symposium on Wednesday, March 16, 2023.

CardioFocus Announces Pulsed Field Ablation Milestones

Retrieved on: 
Tuesday, July 19, 2022
Stroke, SS, Electrode, Patient, Contact force, Disease, Disease burden, Safety, Freedom, Data, Ventricular fibrillation, Review, Longevity, Electroporation, Arrhythmia, Technology, Disability, Atrium (heart), RF, Catheter, HRS, Consultant, Physician, CAB, Dementia, Heartlight, PFA, Femoral vein, Heart failure, PVI, RAPID, Pharmaceutical industry, Medical imaging, Medical device, Liquor, Atrial fibrillation

PFA offers the potential of reducing certain safety concerns such as esophageal heating while performing cardiac ablation for Afib.

Key Points: 
  • PFA offers the potential of reducing certain safety concerns such as esophageal heating while performing cardiac ablation for Afib.
  • Patents for HeartLight PFA technology were filed earlier this year, and CardioFocus anticipates first human use in early 2023.
  • 1Nakagawa et al., B-PO03-131 Effects of Contact Force on Lesion Size During Pulsed Field Ablation, Heart Rhythm, Vol.
  • 3 All members of the Clinical Advisory Board are consultants of CardioFocus for the development of the HeartLight Pulse Field Ablation System.

Research launched at Global Forum on Nicotine shows WHO's tobacco control measures are failing - and that harm reduction works

Retrieved on: 
Friday, June 17, 2022
Smoker, Tobacco, Mortality, Smoking, Framework convention, Science, Global Burden of Disease Study, WHO, Association, FCTC, Man, Research, TCS, Sale, WHO Framework Convention on Tobacco Control, Disease burden, Male, Woman, Nicotine, EU

WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.

Key Points: 
  • WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.
  • Instead, the independent research , conducted by distinguished tobacco dependence researcher Dr Lars M. Ramstrm , shows that switching from smoking to Swedish-style snus, a safer nicotine product, is a more effective strategy to reduce the harms caused by tobacco.
  • Presented to hundreds of delegates, as well as over 50 international experts on tobacco and nicotine science who are speaking at #GFN22, the new findings provide further evidence that the WHO must embrace tobacco harm reduction as part of its global tobacco control response by supporting the use of safer nicotine products to quit smoking.
  • Comprising six measures, it aims to reduce the demand for tobacco.

Research launched at Global Forum on Nicotine shows WHO's tobacco control measures are failing - and that harm reduction works

Retrieved on: 
Friday, June 17, 2022
Smoker, Tobacco, Mortality, Smoking, Framework convention, Science, Global Burden of Disease Study, WHO, Association, FCTC, Man, Research, TCS, Sale, WHO Framework Convention on Tobacco Control, Disease burden, Male, Woman, Nicotine, EU

WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.

Key Points: 
  • WARSAW, Poland, June 17, 2022 /PRNewswire/ -- A new study launched at the ninth annual Global Forum on Nicotine (#GFN22) in Warsaw shows implementation of the WHO's tobacco control measures known as MPOWER has no clear association with low-levels of tobacco-related mortality in Europe.
  • Instead, the independent research , conducted by distinguished tobacco dependence researcher Dr Lars M. Ramstrm , shows that switching from smoking to Swedish-style snus, a safer nicotine product, is a more effective strategy to reduce the harms caused by tobacco.
  • Presented to hundreds of delegates, as well as over 50 international experts on tobacco and nicotine science who are speaking at #GFN22, the new findings provide further evidence that the WHO must embrace tobacco harm reduction as part of its global tobacco control response by supporting the use of safer nicotine products to quit smoking.
  • Comprising six measures, it aims to reduce the demand for tobacco.

Lundbeck to Present New Data at AAN 2022 Adding to Clinical Evidence Regarding VYEPTI

Retrieved on: 
Saturday, April 2, 2022
Health, Managed Care, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, CGRP, Angioedema, Disability, Caregiver, Barbiturate, MMD, Research, Eptinezumab, Neurological disorder, Hives, Poster, MOH, JAMA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LUN, Medicine, History, IV, Marketing, American Academy of Neurology, Disease, YLD, Nausea, Cluster headache, Lists of diseases, Rash, Hypersensitivity, Vomiting, Headache, Safety, Anaphylaxis, Disease burden, Month, AHM, MHD (rapper), Intravenous therapy, CM, American Academy, Calcitonin, Common, FDA, Patient, PGIC, Global Burden of Disease Study, Excipient, Woman, Food, Week, Clinical study design, AAN, Pharmaceutical industry, Poultry, Copper, Vaccine, Medical device, Migraine, Neurology, Lundbeck

The proportion reporting no headache and no AHM use increased by 33.8 percentage points and 23.6 percentage points for VYEPTI and placebo groups, respectively.

Key Points: 
  • The proportion reporting no headache and no AHM use increased by 33.8 percentage points and 23.6 percentage points for VYEPTI and placebo groups, respectively.
  • This is the first study to evaluate the efficacy and safety of VYEPTI in people with episodic cluster headache.
  • The efficacy and safety of VYEPTI were demonstrated in two phase 3 clinical trials; episodic migraine in PROMISE 1 and chronic migraine in PROMISE 2.
  • The safety of VYEPTI was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI.

Hypolipidemics Global Market Report 2021 Featuring Abbott Laboratories, Apotex Fermentation, Biocon, Cadila Healthcare and Chunghwa Chem Syn & Biotech - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 2, 2021
Medical Devices, Health, Patient, Degenerative disease, Cholesterol, Evolocumab, Myalgia, Industry, Smoking, GBD, Diet, Prevalence, Amgen, Clinical trial, ACHES, Blood, HMG-CoA, COVID-19, Disease burden, Animal, PCSK9, Apotex, LDL, Efficiency, FDA, Sanofi, Atherosclerosis, Drinking, Pharmacy, Growth, Agent handling, Hypolipoproteinemia, Harvard Medical School, Lipoprotein, Pharmaceutical industry, Dietary supplement

The "Hypolipidemics Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypolipidemics Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the hypolipidemic drugs market are Abbott Laboratories Ltd, Apotex Fermentation Inc., Biocon Limited, Cadila Healthcare Limited and Chunghwa Chem Syn & Biotech Co., Ltd.
  • This industry includes establishments that produce hypolipidemic drugs or agents that lower lipid and lipoproteins levels in the blood.
  • Some of the major hypolipidemic drugs include fibric acid derivatives, bile acid binding resins, nicotinamides, and cholesterol absorption inhibitors.

BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual Meeting

Retrieved on: 
Thursday, November 4, 2021
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Safety, CLL, Research, Technology, Disease, BTK, Global health, Goal, European Union, Twitter, Completeness, Patient, Private Securities Litigation Reform Act, SLL, Mantle cell lymphoma, Disease burden, Associated, U.S. Securities and Exchange Commission, Adult, Marketing, MCL, Novartis, Risk, WM, Company, Bristol Myers Squibb, COVID-19, Tissue, Lymphocytosis, Union, Pharmacokinetics, Chronic lymphocytic leukemia, Lymphoid leukemia, Tislelizumab, Half-life, Jazz Pharmaceuticals, PARP, Therapy, Intellectual property, Health insurance, Pharmaceutical industry, Medical device, Dentistry, BRUKINSA, BeiGene, BRUKINSA, BEIGENE

Because new BTK is continuously synthesized, BRUKINSA was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.

Key Points: 
  • Because new BTK is continuously synthesized, BRUKINSA was specifically designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Complete approval for this indication may be contingent upon results from ongoing randomized, controlled confirmatory clinical trials.
  • Our expansive portfolio is directed by a predominantly internalized clinical development team supporting trials in more than 40 countries.

Match Health Academy Launches Innovative Video-Based Courses on Atrial Fibrillation (AFib)

Retrieved on: 
Thursday, September 30, 2021
Gillum, Diagnosis, William E. McAnulty Jr., Health, Zombie Movies: The Ultimate Guide, Multimedia, Patient, Atrium (heart), Atrial fibrillation, Percy Jackson & the Olympians, Disease, Ventricular fibrillation, Prevalence, Awareness, Risk, Disease burden, Apple, Learning, Alivecor, Fitbit, ECG, Medical device, Medicine

SANTA CLARA,Calif., Sept. 30, 2021 /PRNewswire/ --Match Health Academy has launched three online, expert-guided, video-based courses designed to help patients and their families better understand and manage AFib.

Key Points: 
  • SANTA CLARA,Calif., Sept. 30, 2021 /PRNewswire/ --Match Health Academy has launched three online, expert-guided, video-based courses designed to help patients and their families better understand and manage AFib.
  • The three courses offered include: AFib Essentials, The Ultimate Guide to Afib Nutrition and The Ultimate Guide to Yoga for AFib.
  • The courses are designed to be easy for patients to understand and provide comprehensive information on how to address the condition.
  • Our AFib courses offer a clear, comprehensive and visually engaging approach to learning about managing AFib.